The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review

Mehul DalalGlobal Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USACorrespondence[email protected]
View further author information

Stephen MitchellGlobal Outcomes Research, DRG Abacus, Bicester, HR, UKView further author information

Conor McCloskeyGlobal Outcomes Research, DRG Abacus, Bicester, HR, UKView further author information

Erin ZagadailovGlobal Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information

Ashish GautamGlobal Outcomes Research, Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Stefan K. Barta, Nicholas Liu, Maral DerSarkissian, Rose Chang, Mingchen Ye, Mei Sheng Duh, Andy Surinach, Michelle Fanale & Kristina S. Yu. (2023) Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States. Clinical Lymphoma Myeloma and Leukemia.
Crossref

Lovepreet Singh, Lakhvir Kaur, Gurjeet Singh, R. K. Dhawan, Manjeet Kaur, Navdeep Kaur & Prabhpreet Singh. (2022) Determination of Alteration in Micromeritic Properties of a Solid Dispersion: Brunauer-Emmett-Teller Based Adsorption and Other Structured Approaches. AAPS PharmSciTech 23:6.
Crossref

Khaled Elsayad, Daniel Rolf, Cord Sunderkötter, Carsten Weishaupt, Elisa Christina Müller, Tarek Nawar, Rene Stranzenbach, Elisabeth Livingstone, Rudolf Stadler, Kerstin Steinbrink, Rose K. C. Moritz & Hans Theodor Eich. (2022) Niedrig dosierte Ganzhautelektronenbestrahlung mit oraler Bexaroten‐Erhaltungstherapie beim kutanen T‐Zell‐Lymphom. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 20:3, pages 279-286.
Crossref

Khaled Elsayad, Daniel Rolf, Cord Sunderkötter, Carsten Weishaupt, Elisa Christina Müller, Tarek Nawar, Rene Stranzenbach, Elisabeth Livingstone, Rudolf Stadler, Kerstin Steinbrink, Rose K. C. Moritz & Hans Theodor Eich. (2022) Low‐dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T‐cell lymphoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 20:3, pages 279-285.
Crossref

G. Dobos, M. Miladi, L. Michel, C. Ram-Wolff, M. Battistella, M. Bagot & A. de Masson. (2022) Recent advances on cutaneous lymphoma epidemiology. La Presse Médicale 51:1, pages 104108.
Crossref

R. Ottevanger, S. Beugen, A.W.M. Evers, R. Willemze, M.H. Vermeer & K.D. Quint. (2021) Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature. Journal of the European Academy of Dermatology and Venereology 35:12, pages 2377-2387.
Crossref

T.S. Bhat, C.M. Herbosa, A.R. Rosenberg, O. Sogade, D.B. Jeffe, N. Mehta‐Shah, Y.R. Semenov & A.C. Musiek. (2020) Current measures are not sufficient: an interview‐based qualitative assessment of quality of life in cutaneous T‐cell lymphoma*. British Journal of Dermatology 184:2, pages 310-318.
Crossref

The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date